Page last updated: 2024-12-04

pd 173074

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1401
CHEMBL ID189584
CHEBI ID63448
SCHEMBL ID177946
MeSH IDM0297822

Synonyms (76)

Synonym
chembl189584 ,
3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea
pyrido[2,3-d]pyrimidine 12
n-(tert-butyl)-n -[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea
bdbm6190
HY-10321
pd-0173074
pd-173074
pd 173074, >=96% (hplc), powder
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea
pd 173074 ,
2FGI ,
NCGC00165863-01
pd173074 ,
smr000568412
MLS001074892
219580-11-7
1-tert-butyl-3-[2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea
chebi:63448 ,
pd-173074-d9
1-tert-butyl-3-[2-[4-(diethylamino)butylamino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]urea
1-tert-butyl-3-(2-(4-(diethylamino)butylamino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea
A25450
NCGC00165863-02
HMS2233G17
AKOS016008595
BCP9001065
1-(tert-butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea
FT-0673540
HMS3265F10
HMS3265F09
HMS3265E10
HMS3265E09
BCPP000121
1-tert-butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)pyrido(2,3-d)pyrimidin-7-yl)urea
unii-a4tll8634y
a4tll8634y ,
n-[2-[[4-(diethylamino)butyl]amino] -6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-y l]-n'-(1,1-dimethylethyl)urea
CS-0182
S1264
urea, n-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido(2,3-d)pyrimidin-7-yl)-n'-(1,1-dimethylethyl)-
n-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido(2,3-d)pyrimidin-7-yl)-n'-(1,1-dimethylethyl)urea
c28h41n7o3
gtpl5037
HMS3371E08
MLS006011101
SCHEMBL177946
n-[2-[[4-(diethylamino)butyl]amino]-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-n'-(1,1-dimethylethyl)urea
n-[2-[[4-(diethylamino)butyl]amino]-6-(3,5- dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-n'-(1,1- dimethylethyl)urea
HB3584
AC-24850
HMS3648A10
mfcd08705327
DTXSID30176363
J-523314
n-[2-[[4-(dethylamno)butyl]amno]-6-(3,5-dmethoxyphenyl)pyrdo[2,3-d ]pyrmdn-7-yl]-n'-(1,1-dmethylethyl)urea
EX-A197
HMS3654L09
J-014372
SW218104-2
fgf/vegf receptor tyrosine kinase inhibitor, pd173074 - cas 219580-11-7
Q27088276
AS-16310
1-(tert-butyl)-3-[7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-2-yl]urea
sr-01000837541
P2474
SR-01000837541-2
BCP02368
SB19382
CCG-264881
NCGC00165863-17
fgf/vegf receptor tyrosine kinase inhibitor
nsc766908
nsc-766908
BP162784
Z2036684790

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Against the background of increasing acquired resistance to FGFR1 inhibitors and our previous work, which partially demonstrated the caspase-3/PARP-mediated antitumor and antimetastatic efficacy of PD173074, a selective FGFR1 inhibitor, against ALDH-high/FGFR1-rich pancreatic ductal adenocarcinoma (PDAC) cells, we investigated the probable synthetic lethality and therapeutic efficacy of targeted PARP inhibition combined with FGFR1 blockade in patients with PDAC."( Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Bamodu, OA; Chao, TY; Chen, JH; Lai, SW; Lee, WH; Wu, AT; Yeh, CT, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Substitution of the C7 position of the pyridopyrimidino core with C2' substituted pyridino moiety increased the in vivo potency and enhanced oral bioavailability of these adenosine kinase inhibitors."( Pyridopyrimidine analogues as novel adenosine kinase inhibitors.
Alexander, KM; Bhagwat, SS; Chu, KL; Gomtsyan, A; Jarvis, MF; Jiang, MQ; Kim, KH; Koenig, JR; Kohlhaas, K; Kowaluk, EA; Lee, C; Mao, Y; Marsh, K; Matulenko, MA; McGaraughty, S; Mikusa, J; Muchmore, S; Perner, RJ; Pratt, JK; Stewart, AO; Wismer, CT; Yu, H; Zheng, GZ, 2001
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In this report, it was observed that combined treatment of a low dosage of curcumin (5-10 µM) with a low concentration (0."( Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.
Chuu, CP; Kuo, LK; Lin, HP, 2012
)
0.38
" Also, increasing the dosage or duration of FGF2 treatment did not significantly alter blastocyst yield or differential cell count (p > 0."( Expression profile of FGF receptors in preimplantation ovine embryos and the effect of FGF2 and PD173074.
Hajian, M; Hosseini, M; Hosseinnia, P; Moradi, M; Nasr-Esfahani, MH; Ostadhosseini, S; Riasi, A, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
fibroblast growth factor receptor antagonistAn antagonist at the fibroblast growth factor receptor.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitorAn EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
pyridopyrimidineAny organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.
ureas
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
biarylAn organic aromatic compound whose structure contains two aromatic rings or ring systems, joined to each other by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Disease1278231
Diseases of signal transduction by growth factor receptors and second messengers26231
Signaling by FGFR in disease335
Signaling by FGFR4 in disease85
FGFR4 mutant receptor activation13

Protein Targets (43)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.79430.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency19.95260.044717.8581100.0000AID485341
glp-1 receptor, partialHomo sapiens (human)Potency4.46680.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504466
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency29.41070.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
EWS/FLI fusion proteinHomo sapiens (human)Potency18.20950.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency12.67280.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency25.28550.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency31.62284.466818.391635.4813AID2107
IDH1Homo sapiens (human)Potency16.36010.005210.865235.4813AID686970
serine-protein kinase ATM isoform aHomo sapiens (human)Potency39.81070.707925.111941.2351AID485349
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
tyrosine-protein kinase YesHomo sapiens (human)Potency9.72320.00005.018279.2586AID686947
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency44.66840.010323.856763.0957AID2662
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.07950.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency8.08300.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency15.00300.031622.3146100.0000AID588579
Interferon betaHomo sapiens (human)Potency29.41070.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Protein (fibroblast Growth Factor (fgf) Receptor 1)Homo sapiens (human)Ki0.04520.04520.04520.0452AID977610
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)IC50 (µMol)20.00000.00040.91515.1000AID242306
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)50.00000.00000.536910.0000AID383062
Platelet-derived growth factor receptor betaMus musculus (house mouse)IC50 (µMol)12.00700.00180.75529.5000AID1795845; AID242623
Insulin receptorHomo sapiens (human)IC50 (µMol)50.00000.00170.847910.0000AID383308; AID683408
Fibroblast growth factor receptor 1Homo sapiens (human)IC50 (µMol)3.37420.00020.942010.0000AID1431255; AID1626495; AID1795845; AID1845293; AID1912484; AID242478; AID242527; AID248575; AID248789; AID248925; AID325626; AID383081
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)13.50700.00020.533510.0000AID1795845; AID383083
Vascular endothelial growth factor receptor 1 Homo sapiens (human)IC50 (µMol)0.19000.00010.29147.0000AID248890
Platelet-derived growth factor receptor alphaRattus norvegicus (Norway rat)IC50 (µMol)17.00000.00500.77414.0000AID248160
Fibroblast growth factor receptor 2Homo sapiens (human)IC50 (µMol)2.61040.00040.32768.6200AID1431256; AID1912485; AID248575; AID248789; AID248925
Fibroblast growth factor receptor 4Homo sapiens (human)IC50 (µMol)3.65020.00080.62178.6200AID1912487; AID248575; AID248789; AID248925
Fibroblast growth factor receptor 3Homo sapiens (human)IC50 (µMol)3.27010.00040.28638.6200AID1912486; AID248575; AID248789; AID248925
Vascular endothelial growth factor receptor 3Homo sapiens (human)IC50 (µMol)0.19000.00010.22644.9000AID248890
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC50 (µMol)0.13250.00000.48308.8000AID1626494; AID1795846; AID242345; AID248890
Tyrosine-protein kinase CSKHomo sapiens (human)IC50 (µMol)19.80000.00131.33525.1800AID325755
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)IC50 (µMol)50.00000.00020.68139.7000AID683407
Platelet-derived growth factor receptor betaRattus norvegicus (Norway rat)IC50 (µMol)17.00000.00500.71284.0000AID248160
Serine-protein kinase ATMHomo sapiens (human)IC50 (µMol)17.60000.00200.29173.4200AID325749
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fibroblast growth factor receptor 1Homo sapiens (human)EC50 (µMol)0.02100.02100.42901.1000AID383087
Fibroblast growth factor receptor 3Homo sapiens (human)EC50 (µMol)0.03000.03000.03000.0300AID383346
Vascular endothelial growth factor receptor 2Homo sapiens (human)EC50 (µMol)0.25000.03600.66642.5000AID383110
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (544)

Processvia Protein(s)Taxonomy
regulation of cell cycleProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell differentiationProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell adhesionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
innate immune responseProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of MAP kinase activityInsulin receptorHomo sapiens (human)
positive regulation of protein phosphorylationInsulin receptorHomo sapiens (human)
positive regulation of receptor internalizationInsulin receptorHomo sapiens (human)
heart morphogenesisInsulin receptorHomo sapiens (human)
regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
protein phosphorylationInsulin receptorHomo sapiens (human)
receptor-mediated endocytosisInsulin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayInsulin receptorHomo sapiens (human)
learningInsulin receptorHomo sapiens (human)
memoryInsulin receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptorHomo sapiens (human)
epidermis developmentInsulin receptorHomo sapiens (human)
male gonad developmentInsulin receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationInsulin receptorHomo sapiens (human)
male sex determinationInsulin receptorHomo sapiens (human)
adrenal gland developmentInsulin receptorHomo sapiens (human)
positive regulation of cell migrationInsulin receptorHomo sapiens (human)
exocrine pancreas developmentInsulin receptorHomo sapiens (human)
receptor internalizationInsulin receptorHomo sapiens (human)
activation of protein kinase activityInsulin receptorHomo sapiens (human)
activation of protein kinase B activityInsulin receptorHomo sapiens (human)
cellular response to insulin stimulusInsulin receptorHomo sapiens (human)
glucose homeostasisInsulin receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin receptorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycogen biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycolytic processInsulin receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionInsulin receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
regulation of embryonic developmentInsulin receptorHomo sapiens (human)
positive regulation of glucose importInsulin receptorHomo sapiens (human)
symbiont entry into host cellInsulin receptorHomo sapiens (human)
protein autophosphorylationInsulin receptorHomo sapiens (human)
positive regulation of developmental growthInsulin receptorHomo sapiens (human)
positive regulation of meiotic cell cycleInsulin receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin receptorHomo sapiens (human)
positive regulation of respiratory burstInsulin receptorHomo sapiens (human)
cellular response to growth factor stimulusInsulin receptorHomo sapiens (human)
dendritic spine maintenanceInsulin receptorHomo sapiens (human)
amyloid-beta clearanceInsulin receptorHomo sapiens (human)
transport across blood-brain barrierInsulin receptorHomo sapiens (human)
neuron projection maintenanceInsulin receptorHomo sapiens (human)
regulation of female gonad developmentInsulin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptorHomo sapiens (human)
multicellular organism developmentInsulin receptorHomo sapiens (human)
positive regulation of kinase activityInsulin receptorHomo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 1Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 1Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 1Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 1Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
organ inductionFibroblast growth factor receptor 1Homo sapiens (human)
neuron migrationFibroblast growth factor receptor 1Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
sensory perception of soundFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
gene expressionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase C activityFibroblast growth factor receptor 1Homo sapiens (human)
regulation of phosphate transportFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 1Homo sapiens (human)
cell projection assemblyFibroblast growth factor receptor 1Homo sapiens (human)
embryonic limb morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 1Homo sapiens (human)
neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 1Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
outer ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
middle ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
chordate embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAP kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusFibroblast growth factor receptor 1Homo sapiens (human)
regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
phosphatidylinositol-mediated signalingFibroblast growth factor receptor 1Homo sapiens (human)
paraxial mesoderm developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of lateral mesodermal cell fate specificationFibroblast growth factor receptor 1Homo sapiens (human)
cell maturationFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
stem cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 1Homo sapiens (human)
calcium ion homeostasisFibroblast growth factor receptor 1Homo sapiens (human)
cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
auditory receptor cell developmentFibroblast growth factor receptor 1Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingFibroblast growth factor receptor 1Homo sapiens (human)
vitamin D3 metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
diphosphate metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
cementum mineralizationFibroblast growth factor receptor 1Homo sapiens (human)
stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of fibroblast growth factor productionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mitotic cell cycle DNA replicationFibroblast growth factor receptor 1Homo sapiens (human)
response to sodium phosphateFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of parathyroid hormone secretionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisFibroblast growth factor receptor 1Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway in absence of ligandFibroblast growth factor receptor 1Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
monocyte chemotaxisVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phospholipase C activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell differentiationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAP kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
embryonic morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 1 Homo sapiens (human)
negative regulation of vascular endothelial cell proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
hyaloid vascular plexus regressionVascular endothelial growth factor receptor 1 Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 2Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 2Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
outflow tract septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
membranous septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 2Homo sapiens (human)
apoptotic processFibroblast growth factor receptor 2Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 2Homo sapiens (human)
axonogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smoothened signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
post-embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic pattern specificationFibroblast growth factor receptor 2Homo sapiens (human)
animal organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of keratinocyte proliferationFibroblast growth factor receptor 2Homo sapiens (human)
morphogenesis of embryonic epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 2Homo sapiens (human)
pyramidal neuron developmentFibroblast growth factor receptor 2Homo sapiens (human)
gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 2Homo sapiens (human)
lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 2Homo sapiens (human)
otic vesicle formationFibroblast growth factor receptor 2Homo sapiens (human)
hair follicle morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
response to lipopolysaccharideFibroblast growth factor receptor 2Homo sapiens (human)
lacrimal gland developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast proliferationFibroblast growth factor receptor 2Homo sapiens (human)
organ growthFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cellFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in hemopoiesisFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrowFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
odontogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cell fate commitmentFibroblast growth factor receptor 2Homo sapiens (human)
response to ethanolFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell cycleFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
lung alveolus developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesodermal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
embryonic digestive tract morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
digestive tract developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ developmentFibroblast growth factor receptor 2Homo sapiens (human)
reproductive structure developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic cranial skeleton morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
epidermis morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching morphogenesis of a nerveFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smooth muscle cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell divisionFibroblast growth factor receptor 2Homo sapiens (human)
ventricular cardiac muscle tissue morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
limb bud formationFibroblast growth factor receptor 2Homo sapiens (human)
bone developmentFibroblast growth factor receptor 2Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
bud elongation involved in lung branchingFibroblast growth factor receptor 2Homo sapiens (human)
lung lobe morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in lung morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord elongationFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
squamous basal epithelial stem cell differentiation involved in prostate gland acinus developmentFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in mammary gland specificationFibroblast growth factor receptor 2Homo sapiens (human)
lateral sprouting from an epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
mammary gland bud formationFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branch elongation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in labyrinthine layer morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
regulation of morphogenesis of a branching structureFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to retinoic acidFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to hypoxiaFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
response to bile acidFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of gene expressionFibroblast growth factor receptor 4Homo sapiens (human)
regulation of extracellular matrix disassemblyFibroblast growth factor receptor 4Homo sapiens (human)
cell migrationFibroblast growth factor receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
regulation of lipid metabolic processFibroblast growth factor receptor 4Homo sapiens (human)
glucose homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
cholesterol homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of catalytic activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of proteolysisFibroblast growth factor receptor 4Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
phosphate ion homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 4Homo sapiens (human)
regulation of bile acid biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of DNA biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 3Homo sapiens (human)
endochondral ossificationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 3Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATFibroblast growth factor receptor 3Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 3Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte proliferationFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
negative regulation of developmental growthFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 3Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 3Homo sapiens (human)
bone maturationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor apoptotic signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
vasculature developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymphangiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
sprouting angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
respiratory system processVascular endothelial growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
negative regulation of apoptotic processVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of JNK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of blood vessel remodelingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein kinase C signalingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
branching involved in blood vessel morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of macroautophagyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial depolarizationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial fissionVascular endothelial growth factor receptor 2Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
ovarian follicle developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell maturationVascular endothelial growth factor receptor 2Homo sapiens (human)
endocardium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of cell shapeVascular endothelial growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of gene expressionVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of BMP signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
embryonic hemopoiesisVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
surfactant homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of neuron apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
cell fate commitmentVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
post-embryonic camera-type eye morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of focal adhesion assemblyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 2Homo sapiens (human)
calcium ion homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
blood vessel endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular wound healingVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
semaphorin-plexin signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of bone developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to hydrogen sulfideVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceTyrosine-protein kinase CSKHomo sapiens (human)
T cell costimulationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of Golgi to plasma membrane protein transportTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of bone resorptionTyrosine-protein kinase CSKHomo sapiens (human)
oligodendrocyte differentiationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of phagocytosisTyrosine-protein kinase CSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase CSKHomo sapiens (human)
cellular response to peptide hormone stimulusTyrosine-protein kinase CSKHomo sapiens (human)
regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
adherens junction organizationTyrosine-protein kinase CSKHomo sapiens (human)
chemotaxisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
negative regulation of cell population proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cerebellar cortex formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
keratinocyte differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
type B pancreatic cell proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cell motilityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Bergmann glial cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
placenta blood vessel developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
labyrinthine layer developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
neuron differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of telomerase activitySerine-protein kinase ATMHomo sapiens (human)
DNA damage responseSerine-protein kinase ATMHomo sapiens (human)
peptidyl-serine autophosphorylationSerine-protein kinase ATMHomo sapiens (human)
DNA damage checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
pexophagySerine-protein kinase ATMHomo sapiens (human)
double-strand break repair via homologous recombinationSerine-protein kinase ATMHomo sapiens (human)
DNA double-strand break processingSerine-protein kinase ATMHomo sapiens (human)
ovarian follicle developmentSerine-protein kinase ATMHomo sapiens (human)
response to hypoxiaSerine-protein kinase ATMHomo sapiens (human)
somitogenesisSerine-protein kinase ATMHomo sapiens (human)
pre-B cell allelic exclusionSerine-protein kinase ATMHomo sapiens (human)
double-strand break repairSerine-protein kinase ATMHomo sapiens (human)
double-strand break repair via nonhomologous end joiningSerine-protein kinase ATMHomo sapiens (human)
chromatin remodelingSerine-protein kinase ATMHomo sapiens (human)
protein phosphorylationSerine-protein kinase ATMHomo sapiens (human)
DNA damage responseSerine-protein kinase ATMHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine-protein kinase ATMHomo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine-protein kinase ATMHomo sapiens (human)
reciprocal meiotic recombinationSerine-protein kinase ATMHomo sapiens (human)
male meiotic nuclear divisionSerine-protein kinase ATMHomo sapiens (human)
female meiotic nuclear divisionSerine-protein kinase ATMHomo sapiens (human)
signal transductionSerine-protein kinase ATMHomo sapiens (human)
brain developmentSerine-protein kinase ATMHomo sapiens (human)
heart developmentSerine-protein kinase ATMHomo sapiens (human)
determination of adult lifespanSerine-protein kinase ATMHomo sapiens (human)
post-embryonic developmentSerine-protein kinase ATMHomo sapiens (human)
response to ionizing radiationSerine-protein kinase ATMHomo sapiens (human)
regulation of autophagySerine-protein kinase ATMHomo sapiens (human)
positive regulation of gene expressionSerine-protein kinase ATMHomo sapiens (human)
peptidyl-serine phosphorylationSerine-protein kinase ATMHomo sapiens (human)
positive regulation of cell migrationSerine-protein kinase ATMHomo sapiens (human)
negative regulation of B cell proliferationSerine-protein kinase ATMHomo sapiens (human)
regulation of telomere maintenance via telomeraseSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine-protein kinase ATMHomo sapiens (human)
V(D)J recombinationSerine-protein kinase ATMHomo sapiens (human)
cellular response to reactive oxygen speciesSerine-protein kinase ATMHomo sapiens (human)
multicellular organism growthSerine-protein kinase ATMHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSerine-protein kinase ATMHomo sapiens (human)
lipoprotein catabolic processSerine-protein kinase ATMHomo sapiens (human)
signal transduction in response to DNA damageSerine-protein kinase ATMHomo sapiens (human)
regulation of apoptotic processSerine-protein kinase ATMHomo sapiens (human)
positive regulation of apoptotic processSerine-protein kinase ATMHomo sapiens (human)
positive regulation of DNA damage response, signal transduction by p53 class mediatorSerine-protein kinase ATMHomo sapiens (human)
positive regulation of neuron apoptotic processSerine-protein kinase ATMHomo sapiens (human)
meiotic telomere clusteringSerine-protein kinase ATMHomo sapiens (human)
positive regulation of cell adhesionSerine-protein kinase ATMHomo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine-protein kinase ATMHomo sapiens (human)
protein autophosphorylationSerine-protein kinase ATMHomo sapiens (human)
thymus developmentSerine-protein kinase ATMHomo sapiens (human)
oocyte developmentSerine-protein kinase ATMHomo sapiens (human)
neuron apoptotic processSerine-protein kinase ATMHomo sapiens (human)
regulation of cell cycleSerine-protein kinase ATMHomo sapiens (human)
histone mRNA catabolic processSerine-protein kinase ATMHomo sapiens (human)
cellular response to retinoic acidSerine-protein kinase ATMHomo sapiens (human)
cellular response to gamma radiationSerine-protein kinase ATMHomo sapiens (human)
cellular response to X-raySerine-protein kinase ATMHomo sapiens (human)
cellular response to nitrosative stressSerine-protein kinase ATMHomo sapiens (human)
cellular senescenceSerine-protein kinase ATMHomo sapiens (human)
replicative senescenceSerine-protein kinase ATMHomo sapiens (human)
establishment of RNA localization to telomereSerine-protein kinase ATMHomo sapiens (human)
establishment of protein-containing complex localization to telomereSerine-protein kinase ATMHomo sapiens (human)
regulation of cellular response to heatSerine-protein kinase ATMHomo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine-protein kinase ATMHomo sapiens (human)
positive regulation of DNA catabolic processSerine-protein kinase ATMHomo sapiens (human)
regulation of microglial cell activationSerine-protein kinase ATMHomo sapiens (human)
negative regulation of TORC1 signalingSerine-protein kinase ATMHomo sapiens (human)
negative regulation of telomere cappingSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomere maintenance via telomere lengtheningSerine-protein kinase ATMHomo sapiens (human)
positive regulation of telomerase catalytic core complex assemblySerine-protein kinase ATMHomo sapiens (human)
regulation of autophagosome assemblySerine-protein kinase ATMHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageSerine-protein kinase ATMHomo sapiens (human)
telomere maintenanceSerine-protein kinase ATMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (83)

Processvia Protein(s)Taxonomy
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
ATP bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
heme bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
connexin bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
amyloid-beta bindingInsulin receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin receptorHomo sapiens (human)
insulin receptor activityInsulin receptorHomo sapiens (human)
insulin-like growth factor receptor bindingInsulin receptorHomo sapiens (human)
protein bindingInsulin receptorHomo sapiens (human)
ATP bindingInsulin receptorHomo sapiens (human)
GTP bindingInsulin receptorHomo sapiens (human)
protein domain specific bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor II bindingInsulin receptorHomo sapiens (human)
cargo receptor activityInsulin receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptorHomo sapiens (human)
insulin bindingInsulin receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin receptorHomo sapiens (human)
protein-containing complex bindingInsulin receptorHomo sapiens (human)
PTB domain bindingInsulin receptorHomo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 1Homo sapiens (human)
protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 1Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 1Homo sapiens (human)
SH2 domain bindingFibroblast growth factor receptor 1Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 1Homo sapiens (human)
receptor-receptor interactionFibroblast growth factor receptor 1Homo sapiens (human)
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
placental growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 2Homo sapiens (human)
protein bindingFibroblast growth factor receptor 2Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 2Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 2Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 4Homo sapiens (human)
protein bindingFibroblast growth factor receptor 4Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 4Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 4Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 3Homo sapiens (human)
protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 3Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein phosphatase bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein homodimerization activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
integrin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
coreceptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
identical protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
cadherin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
Hsp90 protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein kinase A catalytic subunit bindingTyrosine-protein kinase CSKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase CSKHomo sapiens (human)
proline-rich region bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein kinase CSKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
DNA bindingSerine-protein kinase ATMHomo sapiens (human)
protein serine/threonine kinase activitySerine-protein kinase ATMHomo sapiens (human)
DNA-dependent protein kinase activitySerine-protein kinase ATMHomo sapiens (human)
protein bindingSerine-protein kinase ATMHomo sapiens (human)
ATP bindingSerine-protein kinase ATMHomo sapiens (human)
1-phosphatidylinositol-3-kinase activitySerine-protein kinase ATMHomo sapiens (human)
histone H2AXS139 kinase activitySerine-protein kinase ATMHomo sapiens (human)
identical protein bindingSerine-protein kinase ATMHomo sapiens (human)
protein-containing complex bindingSerine-protein kinase ATMHomo sapiens (human)
protein serine kinase activitySerine-protein kinase ATMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Processvia Protein(s)Taxonomy
cytosolProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
nucleusProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cytoskeletonProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
plasma membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
focal adhesionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
endosome membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
cell junctionProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
protein-containing complexProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
plasma membraneProto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear envelopeInsulin receptorHomo sapiens (human)
nuclear lumenInsulin receptorHomo sapiens (human)
lysosomeInsulin receptorHomo sapiens (human)
late endosomeInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
caveolaInsulin receptorHomo sapiens (human)
external side of plasma membraneInsulin receptorHomo sapiens (human)
endosome membraneInsulin receptorHomo sapiens (human)
membraneInsulin receptorHomo sapiens (human)
dendrite membraneInsulin receptorHomo sapiens (human)
neuronal cell body membraneInsulin receptorHomo sapiens (human)
extracellular exosomeInsulin receptorHomo sapiens (human)
insulin receptor complexInsulin receptorHomo sapiens (human)
receptor complexInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
axonInsulin receptorHomo sapiens (human)
extracellular regionFibroblast growth factor receptor 1Homo sapiens (human)
nucleusFibroblast growth factor receptor 1Homo sapiens (human)
cytosolFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
membraneFibroblast growth factor receptor 1Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 1Homo sapiens (human)
receptor complexFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular spaceVascular endothelial growth factor receptor 1 Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
focal adhesionVascular endothelial growth factor receptor 1 Homo sapiens (human)
actin cytoskeletonVascular endothelial growth factor receptor 1 Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
collagen-containing extracellular matrixFibroblast growth factor receptor 2Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 2Homo sapiens (human)
nucleusFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmFibroblast growth factor receptor 2Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
cell cortexFibroblast growth factor receptor 2Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 2Homo sapiens (human)
membraneFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 2Homo sapiens (human)
excitatory synapseFibroblast growth factor receptor 2Homo sapiens (human)
receptor complexFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
cell-cell junctionFibroblast growth factor receptor 4Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 4Homo sapiens (human)
endosomeFibroblast growth factor receptor 4Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 4Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 4Homo sapiens (human)
receptor complexFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
focal adhesionFibroblast growth factor receptor 3Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 3Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 3Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 3Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 3Homo sapiens (human)
receptor complexFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 3Homo sapiens (human)
nucleoplasmVascular endothelial growth factor receptor 3Homo sapiens (human)
cytosolVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 2Homo sapiens (human)
nucleusVascular endothelial growth factor receptor 2Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
early endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
endoplasmic reticulumVascular endothelial growth factor receptor 2Homo sapiens (human)
Golgi apparatusVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
external side of plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
cell junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
membrane raftVascular endothelial growth factor receptor 2Homo sapiens (human)
anchoring junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
sorting endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 2Homo sapiens (human)
cytoplasmTyrosine-protein kinase CSKHomo sapiens (human)
cytosolTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase CSKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
centrosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
plasma membraneDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
chromosome, telomeric regionSerine-protein kinase ATMHomo sapiens (human)
peroxisomal matrixSerine-protein kinase ATMHomo sapiens (human)
site of double-strand breakSerine-protein kinase ATMHomo sapiens (human)
nucleusSerine-protein kinase ATMHomo sapiens (human)
nucleoplasmSerine-protein kinase ATMHomo sapiens (human)
nucleolusSerine-protein kinase ATMHomo sapiens (human)
cytoplasmSerine-protein kinase ATMHomo sapiens (human)
peroxisomal matrixSerine-protein kinase ATMHomo sapiens (human)
centrosomeSerine-protein kinase ATMHomo sapiens (human)
spindleSerine-protein kinase ATMHomo sapiens (human)
cytosolSerine-protein kinase ATMHomo sapiens (human)
cytoplasmic vesicleSerine-protein kinase ATMHomo sapiens (human)
intracellular membrane-bounded organelleSerine-protein kinase ATMHomo sapiens (human)
DNA repair complexSerine-protein kinase ATMHomo sapiens (human)
cytoplasmSerine-protein kinase ATMHomo sapiens (human)
nucleusSerine-protein kinase ATMHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (523)

Assay IDTitleYearJournalArticle
AID1795845Kinase Inhibition Assay from Article 10.1021/jm0500931: \\Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor recepto2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID1795846VEGF-R Kinase Inhibition Assay from Article 10.1021/jm0500931: \\Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor 2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID383610Cytotoxicity against human CAL120 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383393Cytotoxicity against human 639-V cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383908Cytotoxicity against human HCC827cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384891Cytotoxicity against human KYSE510 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383912Cytotoxicity against human HDQ-P1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384896Cytotoxicity against human LCLC-97TM1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1461479Inhibition of FGFR2 in human FGFR2-amplified SUM52 cells assessed as decrease in FGF-induced FGFR2 phosphorylated expression levels at 100 nM preincubated for 30 mins followed by compound washout and incubated under drug free condition for 120 mins and su2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384914Cytotoxicity against human ZR-75-30 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384847Cytotoxicity against human IGR37 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384384Cytotoxicity against human OVKATE cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383907Cytotoxicity against human HCC78 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384905Cytotoxicity against human WiDr cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383873Cytotoxicity against human EVSA-T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384641Cytotoxicity against human NCI-H1435 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383870Cytotoxicity against human EGI1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384653Cytotoxicity against human NCI-H1734 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384206Cytotoxicity against human NCI-H810 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384409Cytotoxicity against human RERF-LC-KJ cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383920Cytotoxicity against human HeLa.P3(s) cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383895Cytotoxicity against human HBE4-E6E7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384429Cytotoxicity against human Lu135 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383596Cytotoxicity against human BT474 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384441Cytotoxicity against human MDA-MB-157 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID248160Inhibition of PDGF-dependent rat glioma cell proliferation2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID383637Cytotoxicity against human COLO 857 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384858Cytotoxicity against human J82 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383642Cytotoxicity against human COLO 679 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384651Cytotoxicity against human NCI-H1693 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384376Cytotoxicity against human OE21 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384186Cytotoxicity against human NCI-H2196 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384631Cytotoxicity against human MKN74 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384375Cytotoxicity against human OE19 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384204Cytotoxicity against human NCI-H661 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384652Cytotoxicity against human NCI-H1703 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384407Cytotoxicity against human RERF-LC-Ad1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384621Cytotoxicity against human MEL-SA/Dx-5 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1815514Cytotoxicity against human SUM52 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter blue viability assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
AID384690Cytotoxicity against human HT115 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384844Cytotoxicity against human HUP-T3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384674Cytotoxicity against human HLF cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383883Cytotoxicity against human G402 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384367Cytotoxicity against human NH6 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384386Cytotoxicity against human OVSAYO cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384843Cytotoxicity against human huH-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384912Cytotoxicity against human YKG1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384434Cytotoxicity against human M059J cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512974Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in capillary tube visibility at 0.3 to 1000 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID383916Cytotoxicity against human HeLa S3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383366Inhibition of PDGF2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383586Cytotoxicity against human AZ521 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383389Cytotoxicity against human 201T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384192Cytotoxicity against human NCI-H2405 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1460997Inhibition of FGFR1 in human FGFR1-amplified H520 cells assessed as decrease in FGF-induced phosphorylated ERK1/2 expression levels at 100 nM preincubated for 30 mins followed by compound washout and incubated under drug free condition for 120 mins and su2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384678Cytotoxicity against human HOS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384389Cytotoxicity against human Panc02.03 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384854Cytotoxicity against human IPC298 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383865Cytotoxicity against human EFM19 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384855Cytotoxicity against human IPTP/98 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383635Cytotoxicity against human COLO 792 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384871Cytotoxicity against human KMRC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384440Cytotoxicity against human MDA-H2774 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384620Cytotoxicity against human MES-SA cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384198Cytotoxicity against human NCI-H460 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383919Cytotoxicity against human HeLa TG Cap cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383398Cytotoxicity against human 8505C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383874Cytotoxicity against human fR2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384875Cytotoxicity against human KP-1NL cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383889Cytotoxicity against human GTL16 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384419Cytotoxicity against human RVH-421 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383888Cytotoxicity against human GP5d cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384890Cytotoxicity against human KYSE50 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384644Cytotoxicity against human NCI-H1568 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512967Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in capillary tube sprouting at 100 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID383867Cytotoxicity against human EFM-192B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383648Cytotoxicity against human COLO 849 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383901Cytotoxicity against human HCC1954 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384851Cytotoxicity against human IM95 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384390Cytotoxicity against human Panc03.27 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384645Cytotoxicity against human NCI-H1573 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384443Cytotoxicity against human MDA-MB-361 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383588Cytotoxicity against human BE(2)-C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384187Cytotoxicity against human NCI-H2228 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID325626Inhibition of FGFR12007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID383400Cytotoxicity against human A2058 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384414Cytotoxicity against human RO82-W-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1626495Inhibition of full length human FGFR1 expressed in baculovirus system using poly (Glu,Tyr)4:1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counting analysis2016ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors.
AID384888Cytotoxicity against human KYSE410 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383632Cytotoxicity against human COLO 205 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383640Cytotoxicity against human COLO 320 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384430Cytotoxicity against human LU99A cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383580Cytotoxicity against human ABC-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383902Cytotoxicity against human HCC366 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383892Cytotoxicity against human H69V cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383576Cytotoxicity against human A375.S2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383890Cytotoxicity against human H3255 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384373Cytotoxicity against human OAW42 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384865Cytotoxicity against human KATO II cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384673Cytotoxicity against human HLE cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383647Cytotoxicity against human COLO 824 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384675Cytotoxicity against human HMCB cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384369Cytotoxicity against human NUGC2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384666Cytotoxicity against human NCI-H2030 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384366Cytotoxicity against human NCI-N87 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383903Cytotoxicity against human HCC38 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512681Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in closed polygon formation at 0.3 to 1000 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID383395Cytotoxicity against human 769-P cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1461480Inhibition of FGFR1 in human FGFR1-amplified H520 cells assessed as decrease in FGF-induced FGFR1 phosphorylated expression levels at 100 nM preincubated for 30 mins followed by compound washout and incubated under drug free condition for 120 mins and sub2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384909Cytotoxicity against human WM35 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383399Cytotoxicity against human A172 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384679Cytotoxicity against human HPAC cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384431Cytotoxicity against human LU99B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383591Cytotoxicity against human BFTC905 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384898Cytotoxicity against human LN18 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383609Cytotoxicity against human Caki1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384199Cytotoxicity against human NCI-H520 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID242345Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID384387Cytotoxicity against human OVTOKO cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384654Cytotoxicity against human NCI-H1755 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384405Cytotoxicity against human RCM1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383905Cytotoxicity against human HCC56 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384899Cytotoxicity against human LN229 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384910Cytotoxicity against human WM793b cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383893Cytotoxicity against human HARA cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384901Cytotoxicity against human VMRC-RCW cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383590Cytotoxicity against human BEN cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384685Cytotoxicity against human Hs 683 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384659Cytotoxicity against human NCI-H1915 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383654Cytotoxicity against human DLD1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383863Cytotoxicity against human DV 90 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383906Cytotoxicity against human HCC70 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383884Cytotoxicity against human GAMG cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384189Cytotoxicity against human NCI-H23 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383627Cytotoxicity against human CL11 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID718819Inhibition of RON at 100 uM2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
AID384381Cytotoxicity against human OVCAR5 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1815515Cytotoxicity against human JMSU-1 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter blue viability assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
AID383359Inhibition of PKC2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID242623Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by mouse platelet-derived growth factor receptor-beta2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID384892Cytotoxicity against human KYSE520 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384635Cytotoxicity against human MS751 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID248575Inhibition of human FGF receptor expressing ovarian carcinoma cell proliferation 2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID383397Cytotoxicity against human 8305C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383611Cytotoxicity against human CAL12T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384421Cytotoxicity against human Saos-2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384861Cytotoxicity against human JIMT1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383862Cytotoxicity against human DU145 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383628Cytotoxicity against human CL14 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383866Cytotoxicity against human EFM192A cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384184Cytotoxicity against human NCI-H2170 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384410Cytotoxicity against human RERF-LC-MS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383606Cytotoxicity against human C-4 II cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384408Cytotoxicity against human RERF-LC-Ad2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID248890Inhibition of VEGF-stimulated human umbilical vein endothelial cell proliferation2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID383388Cytotoxicity against human 1A6 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID683407Inhibition of MEK1 fused with GST by autoradiography2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
AID383871Cytotoxicity against human EJ138 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384859Cytotoxicity against human JHH1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383869Cytotoxicity against human EFO21 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID683408Inhibition of INSR2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
AID384371Cytotoxicity against human NUGC4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384624Cytotoxicity against human MFE-296 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384436Cytotoxicity against human MCAS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383650Cytotoxicity against human COR-L 23/CPR cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383878Cytotoxicity against human FU97 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383864Cytotoxicity against human EBC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383641Cytotoxicity against human COLO 678 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383574Cytotoxicity against human A373-C6 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384618Cytotoxicity against human MEL-HO cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384902Cytotoxicity against human VMRC-RCZ cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383911Cytotoxicity against human HCT8 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383621Cytotoxicity against human Capan2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383909Cytotoxicity against human HCE7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384391Cytotoxicity against human Panc04.03 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384395Cytotoxicity against human PA-TU-8902 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383581Cytotoxicity against human ACHN cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383578Cytotoxicity against human A431 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384438Cytotoxicity against human MCF-7/ADR cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383619Cytotoxicity against human Calu3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384880Cytotoxicity against human KPL1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383638Cytotoxicity against human COLO 858 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384915Cytotoxicity against human SK-NEP1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1461001Antiproliferative activity against human FGFR2-amplified SUM52 cells after 5 days by SRB assay2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID1431255Inhibition of recombinant full length human FGFR1 expressed in baculovirus infected insect cells in presence of [gamma-32P]ATP after 10 mins by scintillation counting based radioactive filter binding assay2017European journal of medicinal chemistry, Jan-27, Volume: 126An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
AID384887Cytotoxicity against human KYSE30 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384400Cytotoxicity against human PC-3[JPC-3] cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384426Cytotoxicity against human LS174T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383629Cytotoxicity against human CL34 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1460990Antiproliferative activity against human FGFR1-amplified NCI-H520 cells after 7 days by SRB assay2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384427Cytotoxicity against human LS180 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383605Cytotoxicity against human C-4 I cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383601Cytotoxicity against human BxPC3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384428Cytotoxicity against human Lu-134-A-H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384365Cytotoxicity against human NCI-H838 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383894Cytotoxicity against human HBE135-E6E7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384422Cytotoxicity against human LNZTA3WT11 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384413Cytotoxicity against human RMG-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383633Cytotoxicity against human COLO 320DM cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384183Cytotoxicity against human NCI-H2135 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384399Cytotoxicity against human PC-3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384649Cytotoxicity against human NCI-H1651 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384889Cytotoxicity against human KYSE450 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383573Cytotoxicity against human A2780 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384893Cytotoxicity against human KYSE70 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383616Cytotoxicity against human CAL62 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512973Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in cell migration at 0.3 to 1000 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID384868Cytotoxicity against human KHM3S cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384418Cytotoxicity against human RT4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID729591Inhibition of RON (unknown origin) at 100 uM after 60 mins by ELISA relative to control2013European journal of medicinal chemistry, Mar, Volume: 61Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
AID384368Cytotoxicity against human Nthyl-ori 3-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384182Cytotoxicity against human NCI-H2122 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384404Cytotoxicity against human QGP1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384416Cytotoxicity against human RT-112 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384885Cytotoxicity against human KYSE220 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384908Cytotoxicity against human WM278 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384897Cytotoxicity against human LK2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384378Cytotoxicity against human ONCO-DG-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383900Cytotoxicity against human HCC1937 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383589Cytotoxicity against human BEAS-2B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512966Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in capillary tube sprouting at 10 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID384203Cytotoxicity against human NCI-H647 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384200Cytotoxicity against human NCI-H522 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384657Cytotoxicity against human NCI-H1793 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384658Cytotoxicity against human NCI-H1869 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384692Cytotoxicity against human HT3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383579Cytotoxicity against human A549 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384398Cytotoxicity against human PC14 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384670Cytotoxicity against human NCI-H2110 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383885Cytotoxicity against human GCT cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384870Cytotoxicity against human KMH2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384691Cytotoxicity against human HT29 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384393Cytotoxicity against human Panc10.05 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384643Cytotoxicity against human NCI-H1563 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383636Cytotoxicity against human COLO 853 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384669Cytotoxicity against human NCI-H2087 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383918Cytotoxicity against human HeLa TG cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1460998Inhibition of FGFR2 in human FGFR2-amplified SUM52 cells assessed as decrease in FGF-induced phosphorylated ERK1/2 expression levels at 100 nM preincubated for 30 mins followed by compound washout and incubated under drug free condition for 120 mins and s2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384681Cytotoxicity against human Hs 257.T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384895Cytotoxicity against human LCLC-103H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384677Cytotoxicity against human HOP92 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383875Cytotoxicity against human FTC133 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384856Cytotoxicity against human Ishikawa cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID242306Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by avian c-Src tyrosine kinase2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID384860Cytotoxicity against human JHH4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1461000Inhibition of FGFR3 in human FGFR3-amplified SW780 cells assessed as decrease in FGF-induced phosphorylated ERK1/2 expression levels at 100 nM preincubated for 30 mins followed by compound washout and incubated under drug free condition for 120 mins and s2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384842Cytotoxicity against human HuCCT1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384903Cytotoxicity against human WI-26 VA4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384663Cytotoxicity against human NCI-H2009 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384396Cytotoxicity against human PA-TU-8988S cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383872Cytotoxicity against human EPLC-272H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383622Cytotoxicity against human CaR1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384852Cytotoxicity against human IM-95m cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1626494Inhibition of VEGFR2 (unknown origin) overexpressed in mouse NIH/ 3T3 cells incubated for 5 mins followed by stimulation with VEGF for 5 mins by immunoblotting analysis2016ACS medicinal chemistry letters, Jun-09, Volume: 7, Issue:6
Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors.
AID384437Cytotoxicity against human MCF7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384866Cytotoxicity against human KATO III cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384907Cytotoxicity against human WM 1552C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383081Inhibition of FGFR12007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383396Cytotoxicity against human 786-O cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383913Cytotoxicity against human HeLa cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384388Cytotoxicity against human PA1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384403Cytotoxicity against human PLC/PRF/5 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384195Cytotoxicity against human NCI-H322 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383615Cytotoxicity against human CAL54 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384638Cytotoxicity against human NB69 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512975Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in capillary tube sprouting at 0.3 to 1000 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID384894Cytotoxicity against human LC-1 sq cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384406Cytotoxicity against human RERF-GC-1B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383584Cytotoxicity against human AsPC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384196Cytotoxicity against human NCI-H358 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384420Cytotoxicity against human S-117 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383346Inhibition of FGFR3 by cellular assay2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383653Cytotoxicity against human Daoy cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383385Cytotoxicity against human 1205Lu cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383915Cytotoxicity against human HeLa AG cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383625Cytotoxicity against human CFPAC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384415Cytotoxicity against human RPMI-7951 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384636Cytotoxicity against human MSTO-211H cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383577Cytotoxicity against human A427 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384397Cytotoxicity against human PA-TU-8988T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383623Cytotoxicity against human CCF-STTG1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384879Cytotoxicity against human KP4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384849Cytotoxicity against human IGROV1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384650Cytotoxicity against human NCI-H1666 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384412Cytotoxicity against human RKN cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383645Cytotoxicity against human COLO 699 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383639Cytotoxicity against human COLO 206F cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384377Cytotoxicity against human OE33 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384435Cytotoxicity against human M14 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384632Cytotoxicity against human ML1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384886Cytotoxicity against human KYSE270 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384628Cytotoxicity against human MKN28 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384671Cytotoxicity against human HGC27 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384877Cytotoxicity against human KP3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383634Cytotoxicity against human COLO 741 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384848Cytotoxicity against human IGR39 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383575Cytotoxicity against human A-375 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383062Inhibition of EGFR2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383594Cytotoxicity against human BIC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383387Cytotoxicity against human 143B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383600Cytotoxicity against human thymidine kinase deficient Bu25 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384683Cytotoxicity against human Hs 578T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384864Cytotoxicity against human JR 029 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384881Cytotoxicity against human KU-19-19 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1460999Inhibition of FGFR3 in human FGFR3-amplified SW780 cells assessed as decrease in FGF-induced phosphorylated ERK1/2 expression levels at 100 nM pretreated for 30 mins followed by FGF stimulation measured after 15 mins by Western blot analysis2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384661Cytotoxicity against human NCI-H196 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383651Cytotoxicity against human COR-L23 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383308Inhibition of InsR2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384402Cytotoxicity against human PL45 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383882Cytotoxicity against human G401 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383886Cytotoxicity against human GMS10 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384202Cytotoxicity against human NCI-H630 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384906Cytotoxicity against human WM 266-4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383914Cytotoxicity against human HeLa 229 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384682Cytotoxicity against human Hs 417.Lu cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID242478Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human FGFR1 in DELFIA assay2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID384680Cytotoxicity against human HRT18 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383881Cytotoxicity against human G361 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384385Cytotoxicity against human OVMIU cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384392Cytotoxicity against human Panc08.13 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1431256Inhibition of FGFR2 (unknown origin)2017European journal of medicinal chemistry, Jan-27, Volume: 126An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors.
AID384439Cytotoxicity against human MC-IXC cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384372Cytotoxicity against human OAW28 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384883Cytotoxicity against human KYSE150 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384857Cytotoxicity against human Ishikawa 02 ER cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383898Cytotoxicity against human HCC15 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383608Cytotoxicity against human Caco-2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383604Cytotoxicity against human C33A cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384616Cytotoxicity against human MDST8 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383917Cytotoxicity against human HeLaS3(sc) cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384442Cytotoxicity against human MDA-MB-231 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1461481Inhibition of FGFR3 in human FGFR3-amplified SW780 cells assessed as decrease in FGF-induced FGFR3 phosphorylated expression levels at 100 nM preincubated for 30 mins followed by compound washout and incubated under drug free condition for 120 mins and su2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384629Cytotoxicity against human MKN45 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383386Cytotoxicity against human 1321N cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384687Cytotoxicity against human Hs 746T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1316518Antiproliferative activity against human RT112 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line.
AID384630Cytotoxicity against human MKN7 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384205Cytotoxicity against human NCI-H727 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384614Cytotoxicity against human MDA-MB-453 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384444Cytotoxicity against human MDA-MB-415 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383597Cytotoxicity against human BT483 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384633Cytotoxicity against human MOG-G-UVW cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384672Cytotoxicity against human HPAF-II cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384637Cytotoxicity against human MT3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID248925Inhibition of FGF-stimulated human umbilical vein endothelial cell proliferation2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID384445Cytotoxicity against human MDA-MB-435S cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID242527Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human fibroblast growth factor receptor 12005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID384379Cytotoxicity against human OUMS23 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383910Cytotoxicity against human HCT116 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384873Cytotoxicity against human KMRM-M1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384374Cytotoxicity against human OCUM1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384878Cytotoxicity against human KP-3L cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383390Cytotoxicity against human 23132/87 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384417Cytotoxicity against human RT112/84 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383618Cytotoxicity against human Calu1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383602Cytotoxicity against human C170 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384693Cytotoxicity against human HTC-C3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384424Cytotoxicity against human LOU-NH91 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383904Cytotoxicity against human HCC44 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384622Cytotoxicity against human MEWO cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383582Cytotoxicity against human AGS cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384664Cytotoxicity against human NCI-H2023 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384188Cytotoxicity against human NCI-H2286 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383595Cytotoxicity against human BICR 78 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384911Cytotoxicity against human YAPC cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384627Cytotoxicity against human MKN1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384846Cytotoxicity against human IGR1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384613Cytotoxicity against human MDA-MB-436 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383646Cytotoxicity against human COLO 818 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383603Cytotoxicity against human C32 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383631Cytotoxicity against human COLO 201 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384916Cytotoxicity against human SK-N-SH cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383868Cytotoxicity against human EFM-192C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID512682Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in mesh-like structure formation at 0.3 to 1000 nM after 14 hrs2006Nature chemical biology, Mar, Volume: 2, Issue:3
A functional genomics approach to the mode of action of apratoxin A.
AID384433Cytotoxicity against human LUDLU1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383626Cytotoxicity against human ChaGo-K-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384884Cytotoxicity against human KYSE180 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383624Cytotoxicity against human CCK81 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383617Cytotoxicity against human CAL-85-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383649Cytotoxicity against human COR-L 105 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384646Cytotoxicity against human NCI-H1581 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384648Cytotoxicity against human NCI-H1650 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1815516Cytotoxicity against human VM-CUB-3 cells assessed as reduction in cell viability incubated for 72 hrs by celltiter blue viability assay2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.
AID384383Cytotoxicity against human OVISE cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384665Cytotoxicity against human NCI-H2029 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384904Cytotoxicity against human WI-38 VA13 sub 2 RA cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1316519Inhibition of human FGFR3 kinase domain (436 to 806 residues) assessed as reduction in ULight-poly GT substrate phosphorylation at 10 uM after 1 hr in presence of ATP by TR-FRET assay2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line.
AID384689Cytotoxicity against human HT 1080 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384668Cytotoxicity against human NCI-H2085 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID325749Inhibition of ATM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID383110Inhibition of VEGFR2 by cellular assay2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383860Cytotoxicity against human DMS 53 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383391Cytotoxicity against human 273T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384411Cytotoxicity against human RERF-LC-Sq1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384640Cytotoxicity against human NCI-H1299 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384197Cytotoxicity against human NCI-H441 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383593Cytotoxicity against human BHT101 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383614Cytotoxicity against human CAL51 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID248789Inhibition of FGF-dependent human umbilical vein endothelial cell proliferation2005Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14
Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyr
AID383585Cytotoxicity against human AU565 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384882Cytotoxicity against human KYSE140 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384660Cytotoxicity against human NCI-H1944 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384662Cytotoxicity against human NCI-H1975 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383599Cytotoxicity against human BT-B cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383897Cytotoxicity against human HCC1395 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384380Cytotoxicity against human OV1063 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384655Cytotoxicity against human NCI-H1781 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384191Cytotoxicity against human NCI-H2347 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384872Cytotoxicity against human KMRC20 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384647Cytotoxicity against human NCI-H1623 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384862Cytotoxicity against human JR 013 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383365Inhibition of Mek2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID325755Inhibition of cSrc2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID384394Cytotoxicity against human PANC1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383583Cytotoxicity against human ASH3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384876Cytotoxicity against human KP2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384432Cytotoxicity against human LU99C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383587Cytotoxicity against human B-CPAP cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384863Cytotoxicity against human JR 019 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID1845293Inhibition of FGFR1 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
AID1460991Antiproliferative activity against human FGFR3-amplified SW780 cells after 5 days by SRB assay2017European journal of medicinal chemistry, Jul-28, Volume: 1352-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
AID384639Cytotoxicity against human NCI-H1048 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384676Cytotoxicity against human HMVII cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384201Cytotoxicity against human NCI-H596 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383598Cytotoxicity against human BT549 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384370Cytotoxicity against human NUGC3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384684Cytotoxicity against human Hs 633T cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384850Cytotoxicity against human IHH4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384667Cytotoxicity against human NCI-H2073 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383607Cytotoxicity against human Ca Ski cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384900Cytotoxicity against human LN405 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384425Cytotoxicity against human LoVo cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383384Cytotoxicity against human 5637 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383592Cytotoxicity against human BFTC909 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384634Cytotoxicity against human MRC9 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384623Cytotoxicity against human MFE280 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384185Cytotoxicity against human NCI-H2172 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384913Cytotoxicity against human ZR-75-1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384190Cytotoxicity against human NCI-H2342 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384626Cytotoxicity against human MIA PaCa-2 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383083Inhibition of Src2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383087Inhibition of FGFR1 by cellular assay2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384382Cytotoxicity against human OVCAR8 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384642Cytotoxicity against human NCI-H1437 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383612Cytotoxicity against human CAL148 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383644Cytotoxicity against human COLO 680N cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384619Cytotoxicity against human MEL-JUSO cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383613Cytotoxicity against human CAL29 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383877Cytotoxicity against human FTC238 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384423Cytotoxicity against human LNZTA3WT4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383887Cytotoxicity against human GOS3 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384401Cytotoxicity against human PC-9 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384867Cytotoxicity against human KG-1-C cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383630Cytotoxicity against human CL40 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383899Cytotoxicity against human HCC1806 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384874Cytotoxicity against human KP-1N cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383392Cytotoxicity against human 42-MG-BA cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383394Cytotoxicity against human 647-V cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384845Cytotoxicity against human HUP-T4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383861Cytotoxicity against human DoTc2 4510 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383891Cytotoxicity against human H4 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384615Cytotoxicity against human MDA-MB-468 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384656Cytotoxicity against human NCI-H1792 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383859Cytotoxicity against human DMS 273 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383652Cytotoxicity against human DAN-G cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384193Cytotoxicity against human NCI-H2444 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384688Cytotoxicity against human Hs 894(E).Lu cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383620Cytotoxicity against human Capan1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384617Cytotoxicity against human ME180 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID383896Cytotoxicity against human HBE4-E6E7-C1 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID384194Cytotoxicity against human NCI-H2452 cells assessed as fraction of viable cells after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Dec-11, Volume: 104, Issue:50
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1811Experimentally measured binding affinity data derived from PDB1998The EMBO journal, Oct-15, Volume: 17, Issue:20
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998The EMBO journal, Oct-15, Volume: 17, Issue:20
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (160)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (1.88)18.2507
2000's42 (26.25)29.6817
2010's100 (62.50)24.3611
2020's15 (9.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.11 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index5.52 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other156 (97.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]